PULMONARY FIBROSIS FOUNDATION AND VERACYTE PARTNER ON SURVEY EXPLORING DIAGNOSTIC EXPERIENCES OF U.S. PATIENTS WITH INTERSTITIAL LUNG DISEASE

Aug 27, 2015, 15:12 PM
announcement_icn_27

PULMONARY FIBROSIS FOUNDATION AND VERACYTE PARTNER ON SURVEY EXPLORING DIAGNOSTIC EXPERIENCES OF U.S. PATIENTS WITH INTERSTITIAL LUNG DISEASE

CHICAGO and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2015 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) and Veracyte, Inc. (NASDAQ: VCYT) announced that the organizations are partnering on a U.S. patient survey to advance understanding of patients' diagnostic experiences with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). The Interstitial Lung Disease Patient Journey (INTENSITY) survey will assess the steps and time required for patients to receive a diagnosis, specific obstacles hindering timely diagnosis, and the physical and emotional impact of patients' diagnostic journey.

Read Full Release

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >